Bio€quity Europe is the premier annual gathering of the corporate and investment communities for the global life sciences industry. Co-organized by BioCentury and EBD Group, it brings together biotech CEOs, venture capitalists, private equity investors, pharma BD&L leaders and financial dealmakers to network, partner and debate the critical issues shaping the biotech industry.

Now in its 26th edition, Bio€quity Europe is the longest-running and most senior-level biotech investor conference in Europe. No biotech event attracts a higher concentration of investors. Although anchored in Europe, Bio€quity Europe is a truly global event, with investors and dealmakers attending from Europe, the United States and Asia. Every European biotech that aspires to globalize — whether by attracting U.S. investors for a NASDAQ IPO, licensing assets to global pharma, or commercializing in the U.S., the world's largest pharma market — will find the right people in the room at Bio€quity Europe.

Past Faculty and delegates have included leaders from Sofinnova Partners, Forbion, Jeito Capital, Gilde Healthcare, EQT Life Sciences, Kurma Partners, Andera Partners, RA Capital, OrbiMed, Novo Holdings, LSP, BioMedPartners, MSD, Bayer, Novartis, Roche, Sanofi, Johnson & Johnson, MoonLake Immunotherapeutics, Candel Therapeutics and many more.

This is the first time Bio€quity Europe travels to Central and Eastern Europe. The region represents a significant and growing opportunity for the global biotech industry, and Prague is at the center of it.

For biotech CEOs, board members and investors attending Bio€quity, Prague offers a front-row seat to learn how to accelerate R&D via clinical trials and manufacturing in Central and Eastern Europe — directly aligned with this year's conference theme on the need for speed. The region is also home to exceptional science with translational potential. Some of the early scientific foundations of Gilead, for example, came from Czech research. Bio€quity Europe in Prague will explore how to take great science from the region and translate it into scalable, venture-backed companies.

Each year Bio€quity Europe rotates to a new European city to spotlight regional innovation ecosystems, with recent editions held in Bruges, San Sebastián, Dublin and Milan.

This year's theme is The Need for Speed: How Europe Can Compete in the New Era. Globally, innovators are finding the need for speed as the driver for investment, partnering and success: speed to the clinic, speed to early human data, and speed to de-risk assets. The question for European biotechs is what strategy they should pursue to compete in this arena, facing new momentum from Asia and an unpredictable landscape in the U.S.

As always, the science in Europe is there. There are more experienced operators than ever before. And after four long years, investor sentiment, finally, is turning. What's needed now is speed.

Bio€quity Europe is a senior-level event designed for decision-makers across the biopharma investment and corporate ecosystem:

• Biotech C-suite: CEOs, CFOs and CBOs of growth-stage biotechnology companies
• Investors: Venture capitalists, private equity investors and corporate venture arms from Europe, the U.S. and Asia
• Pharma BD&L leaders: Business development and licensing executives from global pharmaceutical companies
• Financial dealmakers: Investment bankers and advisors active in life sciences

No biotech event attracts a higher concentration of investors. If you are a European biotech looking to attract global capital, or a U.S. or Asia investor looking to source innovation from Europe, Bio€quity Europe is where the deals get started.

Bio€quity Europe attracts 1,000+ executives and investors from over 30 countries. Although anchored in Europe, the event is truly global, with leading biotech investors attending from the U.S. and Asia alongside Europe's most active VCs and pharma BD&L executives.

Delegates and Faculty at recent Bio€quity Europe events have included leaders from Sofinnova Partners, Forbion, Jeito Capital, Gilde Healthcare, EQT Life Sciences, Kurma Partners, Andera Partners, RA Capital, OrbiMed, Novo Holdings, LSP, BioMedPartners, MSD, Bayer, Novartis, Roche, Sanofi, Johnson & Johnson, MoonLake Immunotherapeutics, Candel Therapeutics, Idorsia and many more.

View the full delegate profile →

This year's program explores how European biotech can accelerate to compete and lead in today's world. Expect strategic panels and debates on:

• How Europe can shorten the path from discovery to the clinic — practical strategies to accelerate development timelines, rapidly reach first-in-human data and de-risk assets to attract investors and pharma
• Where Europe can win as global competition intensifies — a clear-eyed view of how European biotechs can differentiate themselves on the global stage amid rising momentum from Asia and policy uncertainty in the U.S.
• Why Central and Eastern Europe matter now — insights into emerging opportunities, talent pools, cost and operational efficiencies, and partnerships from life sciences leaders in the region

You will also receive an exclusive conference report from Insights Partner McKinsey & Company on European biotech trends, and hear directly from top biotech VCs including partners from Sofinnova, Forbion, Jeito Capital, EQT, Gilde and many more who take the stage as Faculty.

Bio€quity Europe offers two registration categories:

• All-Access General Registration: For biotech, pharma, diagnostics, medical device companies and investors
• All-Access Service Provider Registration: For CROs, CMOs, economic development organizations, law firms, consultants and other service providers

Yes. Bio€quity Europe offers tiered pricing that rewards early registration. Advanced rates are available until April 2, 2026. After that date, standard rates apply. Visit the registration page for current pricing.

Bio€quity Europe sells out every year, so we encourage you to register early to secure your place and the best rate.

Bio€quity Europe is designed to put the right people in the room — senior-level decision-makers from across the global biopharma ecosystem. Your All-Access pass includes:

• Access to the full program of keynotes, fireside chats, strategic panels and debates featuring the Bio€quity Europe Faculty — top VCs such as Sofinnova Partners, Forbion, Jeito Capital, Gilde Healthcare and EQT Life Sciences, alongside biotech CEOs and pharma executives
• Networking receptions, including the Welcome Reception at the National House Vinohrady and the Regional Host Networking Reception at Žofín Palace — meet the investors, CEOs and BD&L leaders who shape the European biotech landscape
• Access to all Presenting Company showcases — up to 120 emerging biotechs selected by BioCentury
• Access to the partneringONE® platform for scheduling one-to-one meetings with investors, pharma BD&L leaders and biotech CEOs
• The exclusive annual McKinsey & Company conference report on European biotech trends

New this year: BioCentury subscribers will have access to an exclusive onsite lounge to check emails, grab a coffee or unwind between meetings.

An official hotel booking portal is available through the Plan Your Visit page on the EBD Group conference website. We strongly encourage delegates to book accommodations early, as Bio€quity Europe sells out and hotel availability near the venue is limited.

Important: EBD Group does not have a third-party hotel booking agency representing this event aside from the official HotelMap link on the website. If you are contacted by any other agency to book accommodation, this is not recommended, as they are unknown to EBD Group and the hotels.

You can begin scheduling one-to-one meetings on March 23, 2026. Before that date, we recommend you access the partneringONE® platform to update your partnering profile — including your bio, company description and areas of interest — so you are ready to partner as soon as scheduling opens.

Your profile will also be visible on partneringONE plus, allowing you to receive messages from potential partners year-round.

Submit a nomination via the Presenting Company Self-Nomination Form. You can also be nominated by a sponsor, Faculty member or other stakeholder.

Please note: Submitting a nomination does not guarantee selection. All nominations are reviewed independently by BioCentury. Invited companies will be subject to a presenting company fee. The Presenting Company track sells out every year, so early nomination is strongly encouraged.

Selected Presenting Companies receive:

• A 12-minute corporate presentation on stage followed by up to three minutes of Q&A from an investor emcee — giving you direct engagement with a senior investor
• One delegate pass to the conference
• Access to all networking events
• Highlighted profile on the partneringONE® platform and in conference marketing, including the conference website
• The ability to post videos and PDFs to the partneringONE® platform
• The ability to nominate companies for additional presenting company slots

Yes. Bio€quity Europe offers a range of sponsorship packages designed to deliver global visibility and position your organization as a leader in the European biotech investment community. Sponsors benefit from thought leadership opportunities (Faculty/moderator roles), branding, delegate passes, access to exclusive networking events, and the ability to nominate presenting companies.

Packages include tiered levels (Gold Sponsor, Silver Sponsor) as well as à la carte opportunities such as Welcome Reception Sponsor, Regional Host Networking Reception Sponsor, Breakfast Sponsor, Wi-Fi Sponsor, Lanyard Sponsor, Fun Run Sponsor, Networking Break Sponsor and more.

Bio€quity Europe 2026 features signature networking events in some of Prague's most iconic venues:

• Welcome Reception at the National House Vinohrady — a stunning Art Nouveau venue in the heart of Prague
• Regional Host Networking Reception at Žofín Palace — a historic island palace on the Vltava River

Sponsorship of these receptions is available. Email us to learn more.

Bio€quity Europe is structured across three in-person days (May 4–6) followed by two digital partnering days (May 12–13). The in-person program includes:

• Keynote addresses and fireside chats with industry leaders
• Strategic panels and debates featuring the Faculty — top VCs, biotech CEOs and pharma executives
• Up to 120 Presenting Company showcases
• One-to-one partnering meetings via partneringONE®
• Networking receptions, including the Welcome Reception at the National House Vinohrady and the Regional Host Networking Reception at Žofín Palace
• An exclusive conference report from Insights Partner McKinsey & Company

Visit the Event Schedule page for the detailed agenda as it becomes available.

Bio€quity Europe's program is shaped by a distinguished Faculty of the industry's most influential leaders — CEOs, investors and pharma executives — who participate as keynote speakers, panelists and moderators. The Faculty drives the strategic debate at the conference each year.

Past Faculty have included partners and leaders from Sofinnova Partners, Forbion, Jeito Capital, Gilde Healthcare, EQT Life Sciences, Kurma Partners, Andera Partners, RA Capital, OrbiMed, Novo Holdings, LSP, BioMedPartners, MSD, Bayer, Roche, Sanofi, Johnson & Johnson, McKinsey & Company and many more. Nearly every major biotech VC in Europe presents their views on stage at Bio€quity Europe.

View this year's Faculty →

Each year Bio€quity Europe features a Regional Host Committee comprising leaders from the host city's life sciences ecosystem. This year's Regional Host Committee in Prague is co-chaired by Prague.Bio and IOCB Tech, and includes representatives from leading Czech and Central European institutions.

The Regional Host Committee helps connect the conference to the local innovation community and highlights regional strengths, opportunities and partnerships.

For all questions related to Bio€quity Europe — registration, sponsorship, presenting, hotel, travel or general inquiries — please contact the BioCentury Corporate Alliances and Business Development team:

Email:conferences@biocentury.com